The FDA has approved Sanofi’s MenQuadfi meningococcal vaccine for infants as young as 6 weeks. Clinical trial data showed 5.3% of infants experienced serious adverse events, including seizures and respiratory failure. Critics say the FDA approved it by comparing it to a similar vaccine, Menveo, despite both showing significant risks. Experts warn this reflects systemic flaws in vaccine safety evaluation.
FDA Approves Meningococcal Vaccine for Infants Without Placebo-Controlled Trials
